hero

Portfolio Careers

Discover opportunities across our network of transformational companies
Amplitude Ventures
Amplitude Ventures
14
companies
31
Jobs
Powered by Getro
Showing 14 companies
Biotechnology
DeepTech
Health
11 - 50
Series B

Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeutic and commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.

Finance
Lending and Investments
11 - 50

Amplitude Venture Capital deploys a growth model that has successfully been used to build Canadian companies with world-class management teams and scale companies to breakout potential. Since 2012 Amplitude's founding team has raised over $700 million of equity capital in private and public markets. Amplitude, with offices in Montreal, Toronto, and Vancouver, launched its first private capital fund in November 2019, a $200-million fund that applies a proven, evidence-based approach to investing in leading Canadian precision medicine companies.

Biotechnology
DeepTech
Health
11 - 50
Series B

Celsius Therapeutics is a community of scientists, technologists, clinicians and drug hunters leveraging single-cell RNA sequencing and genomic analysis to develop life-changing medicines. Our common goal is to markedly improve human health by integrating data, experience and insight. Located in Cambridge, Mass., our environment is rigorous, fast-paced and collaborative, bringing together passionate individuals who are making an impact. We inspire creativity and discovery by embracing an open culture that fosters innovation, teamwork and excellence.

Biotechnology
DeepTech
Health
1 - 10
Series A

Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding.

Biotechnology
Data and Analytics
DeepTech
Health
Software
51 - 200
Series C+

Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.

Biotechnology
Data and Analytics
DeepTech
Health
51 - 200

DrugBank augments human intelligence to improve the world’s health. We offer a suite of products that enable companies to improve healthcare delivery through precision medicine or clinical software application and uncover insights through data science in drug discovery. Our publicly accessible resource, DrugBank Online, has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally.

Evommune
Evommune
3 jobs
Biotechnology
DeepTech
Health
11 - 50
Series B

Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed at combating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles.

Biotechnology
DeepTech
Health
11 - 50
Series A

Gandeeva Therapeutics has developed a proprietary platform that combines innovative technologies across biochemistry, structural biology, imaging and machine learning to characterize protein-drug interactions at the atomic level, all designed to provide new insights into targeting protein function.

Biotechnology
DeepTech
Health
Software
Series A

The notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells.

Prilenia
Prilenia
7 jobs
Biotechnology
DeepTech
Health
11 - 50
Series B

Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. The company was founded in 2018 and is based in Israel, the Netherlands, and Boston.

Biotechnology
DeepTech
Health
51 - 200

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancer treatment both with single therapy and in combination with existing drugs and treatments.

Biotechnology
DeepTech
Health
11 - 50
Seed

Thryv Therapeutics Inc., previously called LQT Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. They have been pioneering a precision medicine approach to treat Long QT Syndrome via SGK1 inhibition since 2019 and have since evolved their portfolio to include the treatment of resistant and rare cancers. The development of SGK1 inhibitors represents a novel approach to target treatment-resistant cancers, and complement existing therapies. This strategic evolution has secured an additional US$15M financing fuelling Thryv to complete a proof-of-concept study for LQTS, and submit an IND for the treatment of resistant cancer. Thérapeutiques Thryv Inc, précédemment appelée Thérapeutiques QTL Inc, est une entreprise privée basée à Montréal, Québec, Canada. Depuis 2019, ils sont les pionniers d'une approche de médecine de précision pour traiter le syndrome du QT long via l'inhibition de SGK-1 et ont depuis évoluer pour inclure le traitement des cancers résistants et rares. Le développement des inhibiteurs de SGK-1 représente une nouvelle approche pour cibler les cancers résistants aux traitements, et compléter les thérapies existantes. Cette évolution stratégique a permis d'obtenir un financement supplémentaire de 15 millions de dollars US qui alimentera Thryv pour compléter une étude de preuve de concept pour le LQTS, et soumettre une IND pour le traitement des cancers résistantes.